[Research Progress in the Pathogenesis of Idiopathic Pulmonary Fibrosis with Lung Cancer]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2020 Aug 26

PMID 32838491

Citations 1

Authors

Chunhui Liu

Yuanbing He

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by diffuse alveolitis and disorder of alveolar structure and eventually leads to pulmonary interstitial fibrosis. The cause of IPF is unknown and there is no effective treatment for IPF. There is no effective treatment for IPF, mainly to delay disease progression and improve patient's quality of life. At present, the incidence of IPF with lung cancer (IPF-LC) has increased significantly, which resulted in higher mortality and reduced quality of life. IPF-LC is more common in men, elderly, and smokers. It is a fatal disease and its clinical manifestations lack specificity. IPF-LC has no clear treatment plan, meanwhile, the median survival time is short, and the prognosis is poor. At present, the pathogenesis and treatment plan of IPF-LC are not clear. This article provides a brief review of the current research on the risk factors, pathogenesis, clinical characteristics and treatment of IPF-LC.

Citing Articles

Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway.

Yu R, Gao D, Bao J, Sun R, Cui M, Mao Y Int J Mol Sci. 2023; 24(4).

PMID: 36835236 PMC: 9965428. DOI: 10.3390/ijms24043818.

References

Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A . PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019; 4(6). PMC: 6482997. DOI: 10.1172/jci.insight.125326. View

Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A . Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clin Lung Cancer. 2017; 19(1):e5-e9. DOI: 10.1016/j.cllc.2017.06.003. View

Kato E, Takayanagi N, Takaku Y, Kagiyama N, Kanauchi T, Ishiguro T . Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018; 4(1). PMC: 5795191. DOI: 10.1183/23120541.00111-2016. View

Kasai H, Allen J, Mason R, Kamimura T, Zhang Z . TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005; 6:56. PMC: 1177991. DOI: 10.1186/1465-9921-6-56. View

Omori T, Tajiri M, Baba T, Ogura T, Iwasawa T, Okudela K . Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. Ann Thorac Surg. 2015; 100(3):954-60. DOI: 10.1016/j.athoracsur.2015.03.094. View

Kaur A, Mathai S, Schwartz D . Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment. Front Med (Lausanne). 2017; 4:154. PMC: 5622313. DOI: 10.3389/fmed.2017.00154. View

Hwang J, Kim D, Chun S, Bae S, Song J, Kim M . Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis. J Pathol. 2017; 244(1):25-35. DOI: 10.1002/path.4978. View

Dai J, Cai H, Zhuang Y, Wu Y, Min H, Li J . Telomerase gene mutations and telomere length shortening in patients with idiopathic pulmonary fibrosis in a Chinese population. Respirology. 2014; 20(1):122-8. DOI: 10.1111/resp.12422. View

Iwata T, Yoshida S, Fujiwara T, Wada H, Nakajima T, Suzuki H . Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis. Ann Thorac Surg. 2016; 102(6):1905-1910. DOI: 10.1016/j.athoracsur.2016.05.094. View

10.

Saito A, Horie M, Micke P, Nagase T . The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. Int J Mol Sci. 2018; 19(11). PMC: 6275044. DOI: 10.3390/ijms19113611. View

11.

Celada L, Kropski J, Herazo-Maya J, Luo W, Creecy A, Abad A . PD-1 up-regulation on CD4 T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med. 2018; 10(460). PMC: 6263177. DOI: 10.1126/scitranslmed.aar8356. View

12.

Roberts A, Wakefield L . The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003; 100(15):8621-3. PMC: 166359. DOI: 10.1073/pnas.1633291100. View

13.

Morikawa M, Derynck R, Miyazono K . TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harb Perspect Biol. 2016; 8(5). PMC: 4852809. DOI: 10.1101/cshperspect.a021873. View

14.

Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T . Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009; 14(5):723-8. DOI: 10.1111/j.1440-1843.2009.01547.x. View

15.

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K . Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2013; 147(5):1604-1611.e3. DOI: 10.1016/j.jtcvs.2013.09.050. View

16.

Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A . The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2010; 71(1):70-4. DOI: 10.1016/j.lungcan.2010.04.014. View

17.

Nagashio R, Ueda J, Ryuge S, Nakashima H, Jiang S, Kobayashi M . Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer. Sci Rep. 2015; 5:8649. PMC: 4346793. DOI: 10.1038/srep08649. View

18.

Duitman J, Ende T, Spek C . Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. J Clin Med. 2019; 8(10). PMC: 6833050. DOI: 10.3390/jcm8101547. View

19.

Liu Y, Zhu M, Geng J, Ban C, Zhang S, Chen W . Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis. Clin Respir J. 2017; 12(4):1700-1705. DOI: 10.1111/crj.12732. View

20.

Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D . Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer. Chest. 2019; 156(2):383-391. DOI: 10.1016/j.chest.2019.04.114. View